Amgen Inc. (NASDAQ:AMGN) Shares Sold by Aull & Monroe Investment Management Corp

Aull & Monroe Investment Management Corp trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 10,514 shares of the medical research company’s stock after selling 490 shares during the period. Amgen comprises approximately 1.4% of Aull & Monroe Investment Management Corp’s portfolio, making the stock its 23rd biggest holding. Aull & Monroe Investment Management Corp’s holdings in Amgen were worth $2,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP purchased a new stake in Amgen during the third quarter worth about $25,000. Centricity Wealth Management LLC purchased a new position in shares of Amgen in the 4th quarter valued at approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen in the third quarter valued at approximately $29,000. Synergy Investment Management LLC acquired a new position in Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC purchased a new position in Amgen during the fourth quarter worth $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on AMGN shares. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Citigroup reiterated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $314.95.

Amgen Trading Up 1.4 %

Shares of NASDAQ AMGN opened at $316.57 on Thursday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The business has a fifty day moving average price of $283.80 and a 200 day moving average price of $299.78. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The stock has a market capitalization of $170.06 billion, a P/E ratio of 41.93, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.01%. Amgen’s payout ratio is currently 126.09%.

Insiders Place Their Bets

In other news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,341 shares of company stock valued at $20,644,335. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.